Table 2.
Patient-, disease-, and transplant-related characteristics by GO total dose
| n (%)* | GO <10 mg Total Dose n = 30 |
GO ≥10 mg Total Dose n = 28 |
|---|---|---|
| Patient-related | ||
| Age at transplant, median (range), years | 41 (19–63) | 47 (21–70) |
| Males | 15 (50) | 13 (46) |
| Karnofsky performance score | ||
| 90–100 | 16 (53) | 15 (54) |
| <90 | 13 (43) | 13 (46) |
| Not reported | 1 (3) | 0 |
| HCT-CI | ||
| 0 | 13 (43) | 9 (32) |
| 1–2 | 9 (30) | 9 (32) |
| ≥3 | 8 (27) | 10 (36) |
| Hepatitis B and C serostatus pre-HCT | ||
| B and C positive | 0 | 1 (4) |
| B positive | 1 (3) | 0 |
| B and C negative | 28 (93) | 26 (93) |
| Not tested/inconclusive | 1 (3) | 1 (4) |
| Disease-related | ||
| Cytogenetics† | ||
| Favorable | 1 (3) | 2 (7) |
| Intermediate | 16 (53) | 20 (71) |
| Poor | 13 (43) | 6 (21) |
| Disease status | ||
| First complete remission | 12 (40) | 8 (29) |
| Second or greater complete remission | 8 (27) | 9 (32) |
| Relapse/primary induction failure | 10 (33) | 11 (39) |
| Transplant-related | ||
| GO administration | ||
| Single-agent GO | 0 | 0 |
| GO plus chemotherapy | 30 (100) | 28 (100) |
| Fractionated dosing | 8 (27) | 11 (39) |
| Cycles of GO before HCT, median (range) | 1 (1–3) | 1 (1–3) |
| Time from receiving GO transplant, median (range), months | 4 (1–12) | 3 (1–15) |
| Conditioning regimen | ||
| Myeloablative–total body irradiation | 9 (30) | 9 (32) |
| Myeloablative–chemotherapy | 21 (70) | 19 (68) |
| Pharmacokinetics for busulfan‡ | 7 (41) | 10 (53) |
| Time from receiving GO to transplant, median (range), months | ||
| First complete remission | 4 (2–7) | 3 (3–7) |
| Second or greater complete remission | 4 (2–9) | 6 (2–15) |
| Relapse/primary induction failure | 4 (1–12) | 2 (1–51) |
| Type of donor | ||
| Related | 11 (37) | 12 (43) |
| Unrelated | 11 (37) | 15 (54) |
| Single cord blood | 2 (7) | 1 (4) |
| Double cord blood | 6 (20) | 0 |
| Donor-recipient CMV match | ||
| Negative, negative | 4 (13) | 10 (36) |
| Positive, negative | 5 (17) | 2 (7) |
| Negative, positive | 12 (40) | 6 (21) |
| Positive, positive | 9 (30) | 8 (29) |
| Not reported | 0 | 2 (7) |
| Donor age, median (range), years§ | 33 (25–45) | 28 (19–44) |
| Graft type | ||
| Bone marrow | 4 (13) | 7 (25) |
| Peripheral blood | 18 (60) | 20 (71) |
| Umbilical cord blood | 8 (27) | 1 (4) |
| GVHD prophylaxis | ||
| Tacrolimus-based | 21 (70) | 27 (96) |
| Cyclosporine-based | 8 (27) | 1 (4) |
| Other | 1 (3) | 0 |
| Sirolimus usage | 1 (3) | 0 |
| ATG/alemtuzumab | ||
| ATG alone | 7 (23) | 5 (18) |
| Alemtuzumab alone | 1 (3) | 0 |
| No ATG or alemtuzumab | 22 (73) | 23 (82) |
| Year of transplant | ||
| 2008 | 12 (40) | .4 (50) |
| 2009 | 13 (43) | 9 (32) |
| 2010 | 5 (17) | 4 (14) |
| 2011 | 0 | 1 (4) |
| Follow-up of survivors, median (range), months | 93 (49–98) | 96 (56–121) |
Unless otherwise noted.
Cytogenetic classification was defined as follows:
Favorable: inv(16), t(16;16), del(16q), t(15;17), [t(8;21) without del(9q) or complex].
Intermediate: normal karyotype, +8, +6, –y, del(12p), t(9;11), 11q23, MLL rearranged, and any other abnormalities not belonging to favorable or poor.
Poor: complex (≥3 abnormalities), –5/5q, –7/7q, abn 3q 9q 11q 21q 17p, t(6;9), t(9;22).
For busulfan-containing regimens only.
For unrelated donors only.
ATG indicates antithymocyte globulin; CMV, cytomegalovirus; GO, gemtuzumab ozogamicin; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplantation-comorbidity index; MLL, mixed lineage leukemia